Why Azenta (AZTA) is on investors’ radar today
Azenta (AZTA) continues to draw attention after a mixed stretch of performance that includes a gain over the past month but weaker returns year to date and over the past year.
With a market value of about US$1.0b and reported revenue of US$596.5m, the company sits in an interesting spot for investors comparing growth potential, profitability and valuation against other life sciences service providers.
See our latest analysis for Azenta.
At the current share price of US$22.71, Azenta’s 30-day share price return of about 18% contrasts with weaker year to date share price performance and multi year total shareholder returns. This suggests that recent momentum is rebuilding from a lower base.
If you are comparing Azenta with other life sciences related opportunities, it could be a useful time to see what else is moving and scan 39 healthcare AI stocks
With Azenta shares still down sharply over the past year but trading about 21% below one intrinsic value estimate and about 15% below one analyst target, is this an overlooked entry point, or is the market already pricing in future growth?
Most Popular Narrative: 24.3% Undervalued
Compared with the last close at $22.71, the most followed narrative points to a Fair Value of $30.00, which implies a meaningful valuation gap.
Biorepositories and next-generation sequencing are seeing healthy demand as pharma and biotech prioritize complex clinical trials and data rich workflows. However, automation investments and regional lab inefficiencies are currently limiting the flow through of that demand into gross margin and adjusted EBITDA.
Want to see what is sitting behind that Fair Value? The narrative leans heavily on steady revenue gains, margin tweaks and a punchy future earnings multiple.
Result: Fair Value of $30 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still risks that could change this narrative, including faster-than-expected cost efficiencies and higher cross-sell across consumables, instruments, and services.
Find out about the key risks to this Azenta narrative.
Next Steps
Given the mixed signals so far, do you see Azenta as underappreciated or fairly valued, and how quickly will you test that view against the data? To understand what investors are optimistic about, review the 3 key rewards
Looking for more investment ideas?
If Azenta has caught your attention, do not stop here. Broaden your watchlist with focused stock ideas that match different investing styles and priorities.
- Target potential mispricing by scanning companies flagged as 47 high quality undervalued stocks that may combine quality fundamentals with prices below one estimate of fair value.
- Prioritize resilience by reviewing 63 resilient stocks with low risk scores featuring stocks that score well on measures of balance sheet strength and business risk.
- Get ahead of the crowd by checking the screener containing 21 high quality undiscovered gems to spot financially sound companies that are not widely followed yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com